Orthofix Medical Inc

Orthofix Medical Inc(OFIX)股票分析

$9.380

-0.205 (-2.19%)收盤時

Loading chart…
最高
9.810
開盤
9.640
成交量加權均價
9.51
成交量
286.07K
市值
505.89M
最低
9.335
成交金額
2.72M
企業價值/稅息折舊攤銷前利潤(TTM)
5.12

Orthofix Medical Inc. is a global medical technology company. It offers a comprehensive portfolio of spinal hardware, bone growth therapies, limb reconstruction solutions, biologics and enabling technologies, including the 7D FLASH Navigation System. Its Global Spine segment offers two primary product categories: bone growth therapies and spinal implants, biologics, and enabling technologies. It provides implantable medical devices, biologics, enabling technologies, and other regenerative solutions which aim to restore the quality of life of patients suffering from diseases and traumas of the spine. It offers a variety of treatment solutions that incorporate multiple treatment modalities, such as mechanical, biological, and electromagnetic modes. Its Global Limb Reconstruction segment offers products and solutions for the underserved limb reconstruction market that encompasses four pillars: deformity correction, limb lengthening, complex fracture management, and limb preservation.

AI 分析 of Orthofix Medical Inc (OFIX)

持有

Orthofix Medical Inc is currently priced at $9.17, which is significantly below the average analyst price target of $13. However, the stock has a negative RSI of 46.37, indicating a potential lack of momentum. The company has also reported a 38.21% year-to-date decline, raising concerns about its long-term viability. While there are positive signs such as a recent revenue beat and an increase in adjusted EBITDA guidance, the ongoing investigation into fiduciary breaches poses a significant risk. Therefore, it may be prudent to hold off on buying until there is more clarity on these issues.

分析師評級(7)

上檔空間 +127.40%
買進
6 買進
1 持有
0 賣出
目前: 9.38
最低
18.00
平均
21.33
最高
24.00

Canaccord

2026-08-10

目標價

$13

買進

Barrington

2026-08-06

目標價

$14

優於大盤

Stifel

2026-08-05

目標價

$13

買進

Stifel

2026-03-09

目標價

$18

買進

Canaccord

2026-02-26

目標價

$20

買進

估值指標

Orthofix Medical Inc(OFIX)目前預期本益比為 500.00,5 年平均預期本益比為 20.67。

預期本益比

嚴重高估
5 年均值 P/E
20.67
目前P/E
500.00
高估
192.72
低估
-151.38

預期 EV/EBITDA

低估
5 年均值 EV/EBITDA
8.93
目前EV/EBITDA
5.12
高估
11.73
低估
6.13

預期股價營收比

低估
5 年均值 P/S
0.78
目前P/S
0.44
高估
1.04
低估
0.51

Alphio AI 對 OFIX 的價格情境

情境價格取自當年最後一個月度預測區間。機率為固定的模型權重(25 / 50 / 25),不構成保證。

樂

樂觀

樂觀 · 25%OFIX

$10.69

情境價格

基

基準

基準 · 50%OFIX

$10.56

情境價格

悲

悲觀

悲觀 · 25%OFIX

$10.47

情境價格

持有 OFIX 的大戶

A

Armistice Capital LLC

+ 持有OFIX

-8.20%

3個月報酬率

事件時間軸

2026-08-05 (ET)

07:30:00

Orthofix Raises 2026 Net Sales Guidance to $845-$855 Million

07:30:00

Orthofix Reports Q2 Revenue of $210.9M, Beating Expectations

2026-07-06 (ET)

09:00:00

Nasdaq and S&P 500 Futures Rise as Chip Stocks Rebound

08:00:00

Orthofix Expects Medicare Reimbursement to Return to Pre-2026 Levels

2026-05-21 (ET)

10:00:00

Stock Down $2.38 to $9.77 in Morning Trading

資訊

OFIX 常見問題 —— 由 Alphio AI 解答

Orthofix Medical Inc. is a global medical technology company. It offers a comprehensive portfolio of spinal hardware, bone growth therapies, limb reconstruction solutions, biologics and enabling technologies, including the 7D FLASH Navigation System. Its Global Spine segment offers two primary product categories: bone growth therapies and spinal implants, biologics, and enabling technologies. It provides implantable medical devices, biologics, enabling technologies, and other regenerative solutions which aim to restore the quality of life of patients suffering from diseases and traumas of the spine. It offers a variety of treatment solutions that incorporate multiple treatment modalities, such as mechanical, biological, and electromagnetic modes. Its Global Limb Reconstruction segment offers products and solutions for the underserved limb reconstruction market that encompasses four pillars: deformity correction, limb lengthening, complex fracture management, and limb preservation. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Orthofix Medical Inc is currently priced at $9.17, which is significantly below the average analyst price target of $13. However, the stock has a negative RSI of 46.37, indicating a potential lack of momentum. The company has also reported a 38.21% year-to-date decline, raising concerns about its long-term viability. While there are positive signs such as a recent revenue beat and an increase in adjusted EBITDA guidance, the ongoing investigation into fiduciary breaches poses a significant risk. Therefore, it may be prudent to hold off on buying until there is more clarity on these issues.

7 analysts cover OFIX: 6 rate it Buy, 1 Hold and 0 Sell. The average price target is 21.33.

暫無貼文

註冊或登入後參與討論

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

開始交易